Nabriva Therapeutics (STU:NTY) Net Change in Cash : €-17.16 Mil (TTM As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Nabriva Therapeutics's Net Change in Cash for the three months ended in Jun. 2023 was €0.31 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was €-17.16 Mil.

Nabriva Therapeutics Net Change in Cash Historical Data

The historical data trend for Nabriva Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Net Change in Cash Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Change in Cash

Get a 7-Day Free Trial

13.39

-14.03

-36.84

5.53

-33.32

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Net Change in Cash	Get a 7-Day Free Trial															-13.05	-5.45	-2.11	-9.92	0.31

Nabriva Therapeutics Net Change in Cash Calculation

Nabriva Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-34.655	+	-0.248	+	1.747	+	-0.164
	=	-33.32

Nabriva Therapeutics's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0.472 + -0.046 + 0 + -0.117

= 0.31

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nabriva Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Nabriva Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (STU:NTY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (STU:NTY) » Definitions » Net Change in Cash

Comparable Companies

BXRX INM ADTX CFRX RUBY SPRC DRMA AMPE NBY SCPS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

NBRVF:USA

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (STU:NTY) Headlines

No Headlines